The symposium “Advancing Amblyopia Care: Innovations in Clinical Trials and Multisensory Approaches in Neuroscience and Auditory Science” concluded successfully in Hong Kong on April 16,2025, with Neu-Direction playing a pivotal role in advancing the dialogue around cutting-edge therapies for amblyopia.
Hosted by the Chinese Academy of Sciences Hong Kong Institute for Innovation in Regenerative Medicine and Health (CRMH), the event brought together global leaders in neuroscience and ophthalmology, including Prof. K.F. So, member of the Chinese Academy of Science, and Prof. Andrew King, Fellow of the Royal Society, and distinguished scholars from institutions such as the City University of Hong Kong, Shanghai Jiao Tong University, Zhongshan Ophthalmic Centre and Precision Sight (Beijing) Medical Technology Co., Ltd.
As a chairman of the event, Prof. Micky Tortorella, chief scientist of CRMH, delivered an opening remark with brief introduction of Neu-001, a novel therapeutic candidate designed to revolutionize amblyopia treatment.
Prof. Jufang He, Department Head of Neuroscience and Director of the Research Centre for Treatments of Brain Disorders, delivered an in-depth presentation on Neu-001’s mechanism of action and its promising clinical potential. His insights underscored the therapy’s ability to harness neuroplasticity and multisensory integration, offering new hope for patients resistant to traditional treatments. During the presentation, Prof. He also highlighted another drug candidate, Neu-002, with potential to address unmet needs in tinnitus treatment.
The symposium served as a dynamic platform for cross-disciplinary collaboration, with Neu-Direction at the forefront of discussions on auditory adaptation, optic nerve regeneration, and innovative therapies like dichoptic movie therapy. The company’s engagement reinforced its commitment to bridging laboratory breakthroughs with real-world clinical applications. Neu-Direction is proud to contribute to this global effort, and we are confident that Neu-001 will soon transition from promising research to life-changing clinical solutions.
